Inventory Management for Just-in-Time (JIT) Delivery in Pharmaceutical Packaging
Introduction: The Evolution of JIT in Pharma
Just-in-Time (JIT) inventory management has long been a cornerstone of operational efficiency across manufacturing industries. Originally pioneered by Japanese manufacturers in the 1980s, JIT brought unprecedented agility to production systems worldwide. For the pharmaceutical packaging industry, however, the adoption of JIT has historically been met with caution—given the chronic concerns over drug shortages, stringent regulatory requirements, and the non-negotiable imperative of patient safety.
Yet the landscape is shifting rapidly. The COVID-19 pandemic fundamentally altered clinical trial designs and supply chain expectations, pushing more pharmaceutical companies to embrace JIT practices for packaging and distribution operations. Today, JIT delivery in pharmaceutical packaging is no longer a luxury—it is a competitive necessity. For packaging partners like Vialab Pharmaceutical Packaging Co., Ltd. , mastering JIT inventory management means delivering safety and reliability together, exactly when healthcare partners need them.
This article explores the strategic importance of JIT inventory management in pharmaceutical packaging, the technologies enabling its success, the regulatory considerations that must be navigated, and best practices for implementation.
The Strategic Imperative for JIT in Pharmaceutical Packaging
Reducing Waste and Optimizing Working Capital
Traditional pharmaceutical packaging operations have relied on a “push” model: manufacturers produce large batches of pre-printed packaging materials, labels, and components based on forecasted demand, then distribute them to depots and sites. This approach often results in significant waste—research shows that many manufacturers over-order pre-printed packaging materials by up to 20% per product line. In the old model, the Pareto principle frequently prevails: 20% of sites end up enrolling 80% of patients, leaving expensive materials sitting unused in warehouses.
JIT flips this model to a “pull” approach: packaging and labeling are standardized and produced on demand, then shipped only when needed. The economic benefits are compelling. According to industry data, a “pull” approach can achieve up to a 75% reduction in overall clinical trial timeframes, alongside dramatic reductions in waste and rework. This is especially critical when each day of delay in a clinical trial costs an estimated $37,000, with opportunity costs ranging from $600,000 to $8 million.
For pharmaceutical packaging manufacturers, JIT inventory management translates directly into reduced warehousing costs, minimized obsolete inventory, and improved cash flow. By maintaining standardized, unprinted packaging components in inventory and applying final labeling only when orders are confirmed, companies can dramatically reduce their inventory footprint. One manufacturer reduced its stock of pre-printed media from 150 variants to fewer than eight, cutting warehouse footprint from 100 pallets to just 10.
Meeting the Demands of Modern Clinical Trials
Today’s clinical trial landscape demands unprecedented flexibility. Adaptive trial designs, rolling site activations, country-specific customization, and direct-to-patient distribution models all require packaging partners to respond with speed and precision. Traditional centralized packaging operations—optimized for long production runs of thousands of kits—are increasingly misaligned with these high-mix, low-volume, fast-turnaround requirements.
Sponsors increasingly favor modular service models that allow them to split packaging functions across multiple providers, leveraging regional logistics hubs for just-in-time labeling near clinical sites. This hybrid approach reduces inventory holding costs, accelerates site activation, and enables rapid response to protocol changes or enrollment variability.
Enabling Technologies for JIT Pharmaceutical Packaging
Digital Printing and Print-on-Demand
Digital printing—or print-on-demand (POD)—has emerged as a transformative technology for JIT pharmaceutical packaging. Unlike conventional printing processes that require as many as 17 steps from art generation to final output, digital printing can function in as little as three steps. Digital systems enable just-in-time printing that allows for shorter production runs while lowering inventory of printed materials and packaged drugs throughout the supply chain.
The benefits extend beyond speed. Digital printing eliminates the need for costly “make-ready” processes that traditionally involve printing hundreds of feet of non-usable material, resulting in minimal waste. Files can be changed, saved, and output directly to the printer, with thousands of designs stored digitally rather than as cumbersome printing plates that become brittle and require remaking.
For pharmaceutical packaging, this means labels, inserts, and cartons can be customized in real time—accommodating different languages, regulatory requirements, or market-specific serialization needs without halting production lines or generating obsolete stock. Digital printing is transforming pharmaceutical packaging “from a cost centre into a strategic asset,” delivering more agility, sustainability, and traceability without compromising patient safety.
White Label Stocking and Postponement Strategies
White label stocking represents a sophisticated inventory management approach perfectly suited for JIT delivery. This strategy involves a packaging partner acting as a custodian for pre-manufactured, unprinted packaging components held in GMP-compliant facilities until final labeling and serialization are required. Coupled with Print on Demand technology, these components are customized in real time at the point of final packaging—ensuring clients receive exactly what they need, exactly when they need it.
The advantages are particularly significant for multi-country distribution. A single batch of product can be prepared and labeled in the final packaging step according to country-specific requirements, languages, or regulatory nuances. This deferred customization reduces the need for multiple SKUs, minimizes inventory complexity, and enables rapid response to regulatory changes or emergency product needs.
Similarly, postponement packaging—a strategy where final packaging is delayed until customer orders are confirmed—offers clients greater control over their supply chains while lowering working capital and reducing finished goods inventories.
Serialization and Track-and-Trace Integration
Regulatory serialization requirements add a layer of complexity to JIT pharmaceutical packaging—but also create opportunities for enhanced inventory visibility. Under the FDA’s Drug Supply Chain Security Act (DSCSA), packaging must include serialization information including GS1 Global Trade Item Number (GTIN), serial number, packaging lot number, and expiration date.
Modern serialization solutions integrate seamlessly with packaging systems to ensure minimal downtime and uninterrupted operations. Quick, tool-free changeovers allow facilities handling diverse or frequently changing packaging formats to maintain efficiency. When integrated with JIT workflows, serialization enables real-time tracking of inventory movements, batch status, and shipment confirmation—ensuring that products remain traceable from production through to the patient.
Regulatory Compliance in JIT Environments
Navigating DSCSA and Global Serialization Requirements
The regulatory environment for pharmaceutical packaging is demanding and ever-evolving. Under DSCSA, every prescription drug package must bear a unique product identifier in a two-dimensional barcode. This product identifier must include the product’s National Drug Code (NDC), a serial number, a lot number, and the expiration date. Effective March 7, 2033, all FDA-assigned NDCs will follow a single 6-4-2 format—a 6-digit labeler code, 4-digit product code, and 2-digit package code.
For JIT packaging operations, compliance means ensuring that serialization data is well-formed and received without errors that could lead to process disruptions or delays. Packaging partners must have validated print-and-apply labeling lines with integration into ERP and serialization databases, along with robust Quality Management Systems aligned with ICH Q10 and GMP requirements.
Maintaining Quality and Integrity
JIT delivery cannot come at the expense of quality. Pharmaceutical packaging components—whether injection pens, sterile vials, or aluminum caps—must meet strict pharmaceutical standards. Cleanroom facilities, advanced production lines, and rigorous quality control processes are non-negotiable.
For JIT operations, this means quality assurance must be built into every step of the workflow. Automated sensors check for damage to packaging or seals. Frequent internal audits validate measurement tools and processes. Third-party validation and ISO/GMP certifications demonstrate commitment to consistency and quality.
Supply Chain Resilience and Risk Management
Building Flexibility into the Supply Chain
JIT inventory management requires a resilient supply chain. Geopolitical tensions in key polymer-producing regions are triggering severe supply chain disruptions and cost volatility for medical packaging manufacturers. Climate-related disasters and geopolitical instability are forcing companies to rethink global production strategies.
To mitigate these risks, pharmaceutical packaging partners must establish supply chain diversity—maintaining relationships with multiple suppliers and strategically locating production facilities. Maintaining a safety stock of critical inventory provides a supply buffer should delays occur, reducing the risk of missing customer deadlines.
Temperature-Controlled Logistics
For many pharmaceutical products, temperature control is a critical component of JIT delivery. Temperature excursions occur in nearly one-third of pharmaceutical shipments. Exposure to extreme temperatures can make medical packaging brittle, risking the contents’ integrity and efficacy.
JIT packaging partners must therefore maintain GMP temperature-controlled storage at ambient (15°C to 25°C), refrigerated (2°C to 8°C), and frozen (-20°C to ±05°C) conditions. Temperature assurance boxes must be preconditioned and delivered just-in-time to the pharma company for shipping products to clinical sites or directly to patients.
Best Practices for JIT Inventory Management in Pharmaceutical Packaging
1. Standardize Early and Often
Successful JIT implementation requires early agreement on what packaging will be used, how drugs will reach patients, and how treatments will be administered. Standardization of packaging components—while allowing for late-stage customization—is essential for JIT efficiency.
2. Invest in Digital Infrastructure
Real-time inventory visibility is foundational to JIT success. Digital inventory systems, cloud-enabled capabilities, and connected solutions support real-time updates and on-demand printing. IoT-enabled packaging solutions linked directly with inventory systems can track stock levels and usage data autonomously, compressing ordering cycles and minimizing administrative burdens.
3. Build Strong Partnerships
Successful CDMO-pharma relationships are built on quality service agreements, transparency, and mutual commitment. Packaging partners should invest in quality assurance, implement digital inventory systems, and develop a culture of transparency with clients. Service agreements provide security for all parties, specifying contract length and delivery commitments.
4. Maintain Buffer Stock Strategically
While JIT minimizes inventory, maintaining a strategic safety stock provides a supply buffer should delays occur. This is particularly important for high-demand generics and critical drug products.
5. Embrace Modular and Flexible Solutions
Modular automation solutions enable true JIT capabilities—multiple small runs delivered quickly under cleanroom conditions. These systems can drastically reduce current timescales, with some innovations aiming to reduce timelines from over 300 days to 30 days.
Conclusion: The Future of JIT in Pharmaceutical Packaging
Just-in-Time inventory management in pharmaceutical packaging is no longer an experimental approach—it is an operational imperative. As clinical trial designs become more complex, regulatory requirements more demanding, and patient expectations higher, packaging partners must deliver with unprecedented speed, flexibility, and precision.
At Vialab Pharmaceutical Packaging Co., Ltd. , we understand that JIT delivery is about more than reducing inventory—it’s about enabling our healthcare partners to respond to patient needs in real time. From injection pens and sterile vials to aluminum caps and customized packaging solutions, every component we manufacture is engineered for consistency, quality, and compliance.
By combining advanced production lines, cleanroom facilities, and rigorous quality control with JIT-enabled technologies like digital printing and white label stocking, Vialab delivers the safety and reliability that global healthcare partners depend on—exactly when they need it.
The pharmaceutical packaging industry is evolving rapidly. Those who master JIT inventory management will lead the way in delivering better patient outcomes, faster.